"Intraaortic Balloon Counterpulsation in Acute Myocardial Infarction-Complicated Cardiogenic Shock"
Links to original sources: Wiki Journal Post Full Journal Article
- Does intraaortic balloon counterpulsation reduce 30-day mortality in patients with acute myocardial infarction-complicated cardiogenic shock who are undergoing early revascularization?
- In patients with cardiogenic shock complicating acute myocardial infarction who were planned for early revascularization, intraaortic balloon counterpulsation did not significantly reduce 30-day all-cause mortality compared to conventional therapy alone.
- Though listed as a Class I treatment in international guidelines for cardiogenic shock complicating acute myocardial infarction, existing evidence supporting intraaortic balloon counterpulsation primarily comes from registry data, with a lack of robust randomized clinical trials. - The IABP-SHOCK II trial, a randomized, open-label, multicenter trial with 600 participants, found no significant difference in 30-day mortality or other secondary endpoints between patients treated with intraaortic balloon counterpulsation and those who received the best available medical therapy without balloon counterpulsation.
- Prior to this study, intraaortic balloon counterpulsation was recommended as Class IB and IC treatment by U.S. and European guidelines, respectively, for cardiogenic shock following acute myocardial infarction.
- Multicenter, open-label, randomized controlled trial with a total of 600 participants. - Interventions: Intraaortic balloon counterpulsation vs. no intraaortic balloon counterpulsation.
- Inclusion Criteria: Patients presenting with acute myocardial infarction (with or without ST-segment elevation) complicated by cardiogenic shock and planned for early revascularization (PCI or CABG). - Exclusion Criteria: Extensive list includes prolonged resuscitation, absent heart action, severe concomitant diseases, and mechanical causes of cardiogenic shock.
- Patients were randomized to intraaortic balloon counterpulsation (IABP group - 301 patients) or a control group without intraaortic balloon counterpulsation (control group - 299 patients).
- Primary Outcome: 30-day all-cause mortality. No significant difference between the groups was observed (IABP group 39.7% vs. control group 41.3% with a relative risk of 0.96). - Secondary Outcomes: No significant differences in secondary clinical endpoints or process-of-care measures including time to hemodynamic stabilization, ICU stay length, lactate levels, catecholamine therapy, renal function, and others.
- Lack of blinding due to nature of the intervention. - Absence of detailed hemodynamic measurements. - Not all patients with severe cardiogenic shock were included, raising questions about the generalizability of the study findings to this subset of patients.
- Funded by the German Research Foundation and others, with unrestricted grants from Maquet Cardiopulmonary and Teleflex Medical.
- New England Journal of Medicine article: "Intraaortic Balloon Counterpulsation in Cardiogenic Shock Complicating Acute Myocardial Infarction" and clinical trial registration number NCT00491036.
ClinicalTrials.gov number, NCT00491036.